CR20220551A - Procesos para la preparación de un inhibidor de cinasa - Google Patents
Procesos para la preparación de un inhibidor de cinasaInfo
- Publication number
- CR20220551A CR20220551A CR20220551A CR20220551A CR20220551A CR 20220551 A CR20220551 A CR 20220551A CR 20220551 A CR20220551 A CR 20220551A CR 20220551 A CR20220551 A CR 20220551A CR 20220551 A CR20220551 A CR 20220551A
- Authority
- CR
- Costa Rica
- Prior art keywords
- processes
- preparation
- compound
- kinase inhibitor
- synthetic preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017739P | 2020-04-30 | 2020-04-30 | |
| PCT/US2021/030035 WO2021222673A1 (en) | 2020-04-30 | 2021-04-30 | Processes for the preparation of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220551A true CR20220551A (es) | 2022-12-07 |
Family
ID=76076455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220551A CR20220551A (es) | 2020-04-30 | 2021-04-30 | Procesos para la preparación de un inhibidor de cinasa |
Country Status (27)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1154105A (zh) | 1994-06-08 | 1997-07-09 | H·隆德贝克有限公司 | 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物 |
| ZA954689B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines |
| SMP200900002B (it) | 2006-06-12 | 2010-01-19 | Novartis Ag | Sali di n-idrossi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide |
| CN101466672B (zh) | 2006-06-12 | 2012-05-16 | 诺瓦提斯公司 | N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐 |
| CA2743416A1 (en) * | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
| TW201920110A (zh) * | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
| WO2012009722A1 (en) * | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| PL2768796T3 (pl) | 2011-10-20 | 2020-05-18 | Exelixis, Inc. | Sposób wytwarzania pochodnych chinoliny |
| EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
| AU2019212800B2 (en) | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| SG11202006945PA (en) | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2021
- 2021-04-30 FI FIEP21727657.5T patent/FI4143169T3/fi active
- 2021-04-30 DK DK21727657.5T patent/DK4143169T3/da active
- 2021-04-30 LT LTEPPCT/US2021/030035T patent/LT4143169T/lt unknown
- 2021-04-30 MA MA59466A patent/MA59466B1/fr unknown
- 2021-04-30 TW TW110115786A patent/TWI887405B/zh active
- 2021-04-30 MX MX2022013528A patent/MX2022013528A/es unknown
- 2021-04-30 SI SI202130435T patent/SI4143169T1/sl unknown
- 2021-04-30 JP JP2022566135A patent/JP7728795B2/ja active Active
- 2021-04-30 US US17/922,208 patent/US12497367B2/en active Active
- 2021-04-30 CA CA3176042A patent/CA3176042A1/en active Pending
- 2021-04-30 KR KR1020227037607A patent/KR20230005190A/ko active Pending
- 2021-04-30 AU AU2021263474A patent/AU2021263474A1/en active Pending
- 2021-04-30 PT PT217276575T patent/PT4143169T/pt unknown
- 2021-04-30 PH PH1/2022/552821A patent/PH12022552821A1/en unknown
- 2021-04-30 CN CN202180031136.7A patent/CN115461328B/zh active Active
- 2021-04-30 CR CR20220551A patent/CR20220551A/es unknown
- 2021-04-30 WO PCT/US2021/030035 patent/WO2021222673A1/en not_active Ceased
- 2021-04-30 EP EP21727657.5A patent/EP4143169B1/en active Active
- 2021-04-30 RS RS20260593A patent/RS68116B1/sr unknown
- 2021-04-30 BR BR112022021712A patent/BR112022021712A2/pt unknown
- 2021-04-30 GE GEAP202516101A patent/GEP20267875B/en unknown
- 2021-04-30 HR HRP20260608TT patent/HRP20260608T1/hr unknown
- 2021-04-30 PE PE2022002513A patent/PE20230110A1/es unknown
- 2021-04-30 SM SM20260219T patent/SMT202600219T1/it unknown
- 2021-04-30 CN CN202511511945.4A patent/CN121591655A/zh active Pending
-
2022
- 2022-10-26 IL IL297684A patent/IL297684B2/en unknown
- 2022-10-26 CO CONC2022/0015205A patent/CO2022015205A2/es unknown
- 2022-10-28 CL CL2022003008A patent/CL2022003008A1/es unknown
-
2025
- 2025-06-20 JP JP2025104881A patent/JP2025128388A/ja active Pending
- 2025-10-21 IL IL324105A patent/IL324105A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024001367A2 (es) | Compuestos antivirales | |
| AR121226A1 (es) | Compuestos y usos de estos | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CO2022015205A2 (es) | Procesos para la preparación de un inhibidor de cinasa | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| MX2023015245A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2. | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| CO2021003391A2 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| MX2025007935A (es) | Nuevos inhibidores reversibles de dpp1 y usos de estos | |
| MX2024011179A (es) | Compuestos multiciclicos | |
| DOP2024000077A (es) | Compuestos de cd73 | |
| AR126196A1 (es) | Proceso para preparar inhibidores de egfr | |
| DOP2025000009A (es) | Inhibidores de acc novedosos | |
| AR116951A1 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| MX2023006176A (es) | Nuevos derivados de indazol acetileno. | |
| AR127561A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| MX2024010402A (es) | Inhibidores de proteinas de union a emopamilo y usos de estos | |
| AR122372A1 (es) | Compuestos y usos de estos | |
| AR132987A1 (es) | Compuestos para el tratamiento de trastornos neurológicos | |
| AR128504A1 (es) | Compuestos antivirales de pirazolopiridinona | |
| AR133607A1 (es) | Inhibidores de la proteína de unión al emopamilo y usos de estos |